Study Evaluating the Safety and Pharmacokinetics of Ascending Single IV Doses of ERB-257

Completed · Phase 1 · Has a placebo group

Conditions studied: Healthy Subjects

In brief

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of ascending single IV doses of ERB-257 in healthy subjects

Key facts

Study ID

NCT00722501

Run by

Wyeth is now a wholly owned subsidiary of Pfizer

People needed

48

Starts

2008-08-01

Expected to finish

2008-11-01

Last updated by the study team

2009-04-28

Who can join

Age: 18 and older, up to 50. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Healthy men and women of non-childbearing potential between the ages of 18 and 50.
• Body mass index (BMI) in the range of 18.0 to 30.0 kg/m2 and body weight greater than or equal to 50 kg2.
• Have a high probability for compliance with and completion of the study.

You may not qualify if…

• Presence or history of any disorder that may prevent the successful completion of the study.
• Acute disease state (eg, nausea, vomiting, fever, or diarrhea) within 7 days before study day 1.

Where it is running

• Trial Manager — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.